Investigators are tackling rheumatology practice challenges, assessing what drives career choices in pediatric rheumatology, improving fellowship training and more—all with the support of the Rheumatology Research Foundation.
ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis
ACR CONVERGENCE 2020—At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after withdrawal of etanercept or methotrexate. Phase 2 Trial of Monoclonal Antibody for Lupus (LILAC) Several converging…
ACR Convergence 2020: COVID-19 Hyper-Inflammation in Kids
ACR CONVERGENCE 2020—Among the many ways in which the COVID-19 pandemic has changed the face of modern medicine is the emergence of multisystem inflammatory syndrome in children (MIS-C), a rare but serious condition that shares many features of Kawasaki disease (KD). With this topic in mind, leading pediatric experts from around the world came together…
Under Pressure: An Update on Pulmonary Hypertension
ACR CONVERGENCE 2020—In patients with connective tissue diseases, such as systemic sclerosis (SSc), pulmonary hypertension (PH) remains one of the leading causes of morbidity and mortality. In her lecture on Friday, Nov. 6, Pulmonary Hypertension: An Update, Mardi Gomberg-Maitland, MD, MSc, professor of medicine and medical director of the Pulmonary Hypertension Program at The George…
The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?
ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…
ACR Convergence 2020: Studies in Rheumatoid Arthritis
ACR CONVERGENCE 2020—Moderated by Bill St.Clair, MD, MACR, an ACR past president and a professor of medicine and immunology at Duke University Medical Center, Durham, N.C., an abstract session on Friday, Nov. 6, focused on the diagnosis, manifestations and outcomes of rheumatoid arthritis (RA), with a focus on interstitial lung disease. RA with ILD Jeffrey…
ACR Convergence 2020 Kicks Off: Plenary session speakers highlight racial differences in lupus & COVID-19-related findings
ACR CONVERGENCE 2020—The ACR’s first fully virtual annual meeting kicked off on Thursday, Nov. 5. During the Opening Session, ACR President Ellen M. Gravallese, MD, talked about how the specialty’s response during the pandemic has provided great hope and will help rheumatology become an even more essential specialty. At the first Plenary Session on Friday,…
Rare Disease Research Provides Insight, Advances in Rheumatic Disease
Technological advances, including disease registries such as ACR’s RISE registry, are improving physicians’ ability to connect disparate patients with similar clinical symptoms, driving insights into both rare and common diseases.
ACR Leads Resolution to Address Copay Accumulator Policies at AMA House of Delegates Meeting
If passed, the ACR-authored resolution will direct the AMA to advocate for copay accumulator bans at state and federal levels. Several other specialties and state medical associations have joined the resolution as cosponsors.
Advancing Rheumatology Care Through State & Local Societies
As his term as chair of the Affiliate Society Council draws to a close, Chris Adams, MD, FACP, FACR, reflects on the personal and professional rewards of volunteer leadership and the importance and impact of coordinated state-level advocacy efforts for the future of rheumatology.
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 304
- Next Page »